NCT00116675

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (planned)
• Sponsor: Graceway Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 3 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.

Conditions

• Warts

Interventions

Type	Name	Description
DRUG	Resiquimod

Timeline

• Start date: 2005-03-01
• Completion: 2006-04-01
• First posted: 2005-07-01
• Last updated: 2007-02-19

Locations

10 sites across 1 country: United States